The Most Expensive AI Mistake in Biotech Isn’t a Hallucination, It’s a Process Failure

Contributed Commentary by Sai Karthik Baira, bioMerieux 

July 24, 2026 | I spend a lot of time talking with scientists, quality leaders, and digital transformation teams across the life sciences industry. The conversation usually starts with excitement: generative AI can summarize protocols, draft reports, search knowledge bases, and accelerate analysis. But when the discussion turns to regulated work, the mood changes. Suddenly, the focus shifts to hallucinations, model accuracy, and whether AI can be trusted. Those are valid concerns. But I think we are asking the wrong first question. 

The most expensive AI failures in biotech and pharma are unlikely to come from a model inventing a sentence. They are more likely to come from organizations treating AI as a standalone tool instead of a controlled business process. 

That distinction matters because regulated life sciences have spent decades building systems around process integrity. We validate software, manage change control, maintain audit trails, and establish accountability. AI does not eliminate those responsibilities. If anything, it magnifies them. 

Real Risk is Context, Not Just Content 

Consider a common scenario. A scientist asks an AI assistant to draft a deviation investigation or summarize experimental results. The generated text may look polished and technically plausible. The risk is not only that a fact is wrong. The larger risk is that the output is disconnected from the governed context in which decisions are made. 

Which data sources were used? Were they current? Were they approved? Who reviewed the output? Could the organization reconstruct how a recommendation influenced a regulated decision six months later? 

These questions may sound mundane compared with debates about large language model capabilities. But they are exactly the questions that determine whether an organization can defend a decision during an inspection, investigation, or legal review. 

In other words, the problem is not merely whether the AI generated something incorrect. The problem is whether the organization can demonstrate that the AI-assisted process remained controlled. 

Why the Pilot Trap Keeps Repeating 

Many organizations launch AI pilots outside their normal governance frameworks because technology is evolving rapidly. Teams want to experiment, and experimentation is important. The danger is that temporary shortcuts often become permanent practices. 

A pilot that begins as a productivity experiment can quietly become part of a quality workflow, a regulatory submission process, or a clinical data review activity. Once that happens, the organization is no longer evaluating a tool. It is operating a business process that influences regulated outcomes. 

This is where traditional software thinking begins to break down. AI systems are not static. Models change. Retrieval sources change. Prompt templates evolve. Even similar prompts can produce different outputs over time. Governance must therefore extend beyond the application itself to encompass the entire AI-assisted process. 

The Shift from Validation to Assurance 

The life sciences industry has already begun moving from document-heavy validation approaches toward more risk-based assurance models. AI accelerates that shift. 

A more useful question than “can we validate the AI?” is, “What level of evidence do we need to demonstrate that this AI-enabled process remains fit for its intended use?” 

The answer depends on risk. For a low-risk administrative task, the evidence may be relatively lightweight. For a process that influences product quality, patient safety, or regulatory reporting, expectations should be considerably higher. 

Instead of trying to prove that an AI system will never make a mistake, organizations should design processes that detect, review, and manage mistakes before they create regulated impact. That is not a new concept, it is a quality principle the industry already understands. 

What Effective AI Assurance Looks Like 

As organizations move from experimentation to operational deployment, effective AI assurance becomes less about the technology itself and more about the controls surrounding it. 

Human accountability must remain explicit. AI can generate recommendations and draft content, but responsibility for regulated decisions cannot be delegated to a model. A qualified individual must remain accountable for review and approval. 

Organizations must also understand data provenance. Teams should know which sources informed an output, whether those sources are approved, and whether they are appropriate for the intended use. 

Transparency matters as well. When necessary, organizations should be able to reconstruct how an AI-generated recommendation was produced and how it influenced a subsequent decision. 

Finally, change management must extend to AI components. Model updates, retrieval-source modifications, and prompt-template revisions should be treated as managed changes rather than invisible background events. 

The Temptation to Automate Judgment 

Perhaps the most important governance question is not technical at all. It is organizational. AI is exceptionally good at generating language, identifying patterns, and accelerating routine analysis. Those capabilities create a natural temptation to automate judgment itself. 

Yet experienced reviewers do more than check facts. They understand context, uncertainty, risk, and consequences. They recognize when a result is unusual, when data is incomplete, or when a conclusion is technically correct but operationally misleading. 

Organizations that view AI as a replacement for expert oversight are likely to create fragile processes. Organizations that view AI as a force multiplier for expert oversight are more likely to create resilient ones. 

A Better Question for Leaders 

When evaluating AI initiatives, I believe leaders should ask a different question: how will we know this process remains controlled after AI is introduced? 

That question shifts the conversation from model performance to process integrity. It forces teams to define accountability, monitoring, change management, and risk controls. The organizations that succeed with AI will not be those that deploy the most models. They will be the ones that integrate AI into governed, measurable, and accountable processes. 

Hallucinations make headlines. Process failures make warning letters, remediation programs, and business-critical consequences. In biotech and pharma, that is the risk worth managing first. 

Sai Karthik Baira, an information systems business analyst at bioMerieux, specializes in electronic quality management systems (eQMS), Laboratory Systems, and enterprise content management within regulated industries. He implements and optimizes digital quality and R&D platforms, including ELN, TrackWise Digital, supporting processes such as CAPA, quality events, change control, and audit management. His focus is on leveraging cloud technologies and data-driven solutions to enhance regulatory compliance and operational efficiency. He can be reached out at [email protected].